Evidence map›Paper›PMID 41776656›Full record

ArticleTrials2026

Continuum of care in hospitalized patients with opioid or stimulant use disorder and infectious complications of drug use-substance use/infectious disease integrated clinic compared to treatment as usual to prevent infection-related readmission (CHOICE-STAR): a study protocol for an effectiveness-implementation randomized controlled trial.

Elana S Rosenthal, Marie-Claude C Lavoie, Edward Traver, Jan Gryczynski, Courtney Nordeck, Joseph E Carpenter, Rebecca Reece, Irene Kuo, Jillian S Catalanotti, Alaina R Steck and 8 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06513156 (Continuum of Care in Hospitalized Patients With Opioid or Stimulant Use Disorder and Infectious Complications of Drug Use - Substance Use/ID Integrated Clinic vs. TAU to Prevent Infection Related Readmission), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06513156 narecruitingnot on this map

Continuum of Care in Hospitalized Patients With Opioid or Stimulant Use Disorder and Infectious Complications of Drug Use - Substance Use/ID Integrated Clinic vs. TAU to Prevent Infection Related Readmission

TypeinterventionalSponsorElana RosenthalRan2024 to 2027Enrolled304ConditionsOpioid Use Disorder, Injection Related Infections, Stimulant Use DisorderArmsIntegrated Infectious Diseases and Substance Use Disorder Clinic (IC)
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Elana S RosenthalInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
Marie-Claude C LavoieInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA. mlavoie@ihv.umaryland.edu.
Edward TraverInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
Jan GryczynskiFriends Research Institute, Baltimore, USA.
Courtney NordeckFriends Research Institute, Baltimore, USA.
Joseph E CarpenterDepartment of Emergency Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Rebecca ReeceDepartment of Medicine, West Virginia University School of Medicine, Morgantown, WV, USA.
Irene KuoDepartment of Epidemiology, Milken Institute School of Public Health, The George Washington University, Washington, DC, USA.
Jillian S CatalanottiDepartment of Medicine, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Alaina R SteckDepartment of Emergency Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Garrett CooperDepartment of Medicine, West Virginia University School of Medicine, Morgantown, WV, USA.
Ayako Wendy FujitaDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, USA.
Sean M MurphyDepartment of Population Health Sciences, Weill Cornell Medical College, New York, New York State, USA.
Megan E MansfieldInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
Habib Omari RamadhaniInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
Rachel SilkInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
Henry MasurNational Institutes of Health, Bethesda, MD, USA.
Sarah KattakuzhyInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.

Funding

NIH HHS 75N90023C00013
6 · The paper itself

Abstract

backgroundPeople who inject drugs (PWID) experience high rates of serious injection-related bacterial and fungal infections (SIRI), including cellulitis, osteomyelitis, and endocarditis. These infections often require prolonged antibiotic treatment and result in frequent rehospitalizations, with over 50% of patients readmitted within 1 year. Few evidence-based interventions exist to optimize continuity of care for addiction, management, and prevention of SIRI following hospitalization.

methodsCHOICE-STAR is a hybrid type 1 randomized effectiveness-implementation trial, guided by the Exploration, Preparation, Implementation, and Sustainment Framework (EPIS), conducted at five hospitals across the USA. The study aims to assess the effectiveness of the integrated infectious diseases (ID) and substance use disorder (SUD) outpatient clinic on 6-month infection-related rehospitalization among people hospitalized with an infection related to injecting opioids or stimulants. The study also includes implementation outcomes guided by Proctor's Implementation Outcomes taxonomy, as well as cost-effectiveness outcomes. The integrated clinic (IC) will offer facilitated linkage to a clinic providing medical care aimed at treating SUD and ID by completing treatment for the index infection, treating existing ID complications of SUD, and preventing subsequent infections by providing low barrier care for SUD including medication for OUD (MOUD) and harm reduction integrated into a single appointment and co-located at a single site for a minimum of monthly appointments over a 6 month time period. An additional 6 months' follow-up will be included to assess outcomes following the completion of the intervention. The IC includes a weekly care coordination meeting between the ID and SUD providers. The study will enroll approximately 304 participants. DISCUSSION: This trial addresses a critical gap in post-hospitalization care for PWID with SIRI. If effective, the integrated care model could significantly reduce rehospitalizations, improve treatment completion, and provide a replicable framework for healthcare systems. The study's implementation science components will inform the scalability and sustainability of this intervention. Results will inform evidence-based policy and practice recommendations for managing this high-risk population, potentially leading to improved patient health outcomes.

trial registrationClinicalTrials.gov NCT06513156 . Registered on August 09, 2024.

Indexed as

Continuity of Patient CareDelivery of Health Care, IntegratedOpioid-Related DisordersPatient ReadmissionSubstance Abuse, IntravenousCentral Nervous System StimulantsHumansMulticenter Studies as TopicRandomized Controlled Trials as TopicTime FactorsTreatment OutcomeUnited StatesCentral Nervous System StimulantsHospitalizationsImplementation scienceInfectious diseasesOpioid use disorderPeople who inject drugsRandomized controlled trialStimulant use disorder

Identifiers

PMID41776656
PMCPMC13067563

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.